Treatment of Nonmetastatic Castration-Resistant Prostate Cancer (CRPC) Higano CS. Does nonmetastatic castration-resistant prostate cancer still exist? Nat Rev Clin Oncol. 2018;15:350-351. Hussain M, Fizazi K, Saad F, et al. PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). J Clin Oncol. 2018;36(suppl): Abstract 3. Shore ND. Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother. 2017;18:945-952. Smith, MR, Saad R, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. New Engl J Med. 2018;378:1408-1418. Yu E. Nonmetastatic castration-resistant prostate cancer, a disease state misnomer that is a seriously unmet therapeutic need. Uro Today. Published March 14, 2017. Accessed June 2018. Treatment of Metastatic CRPC Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402-1418. Lorente D, Mateo J, Perez-Lopez, et al. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol. 2015;16: e279-e292 Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. Published April 18, 2018. Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel vs docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III trial-FIRSTANA. J Clin Oncol. 2017;35:3189-3197. Treatment of Castrate-naïve/Sensitive PC Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352-360. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomized controlled trial. Lancet. 2016;387:1163-1177. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338-351. Sweeny CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737-746. Updated Prostate Cancer Guidelines, Consensus Statements, and Reviews American Society of Clinical Oncology. Optimizing anticancer therapy in metastatic noncastrate prostate cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1521-1539. National Comprehensive Cancer Center Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate Cancer. Version 3.2018. NCCN.org Web site. Published 2018. National Comprehensive Cancer Center Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate Cancer Early Detection. Version 2.2018. NCCN.org Web site. Published 2018. Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378:1653-1654. Biomarkers for Prostate Cancer Treatment Decision-Making Antonarakis ES, Lu C, Luber B, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35:2149-2156. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028-1038. Luo J, Attard G, Balk SP, et al. Role of androgen receptor variants in prostate cancer: report from the 2017 Mission Androgen Receptor Variants meeting. Eur Urol. 2018;73:715-723. Mateo J, Boysen G, Barbieri CE, et al. DNA repair in prostate cancer: biology and clinical implications. Eur Urol. 2017;71:417-425. Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2016;2:1441:1449.